InsiderPulse| Date | Owner | Role | Type | Shares | Price | Value | Owned After | ||
|---|---|---|---|---|---|---|---|---|---|
| 2026-04-28 | Coyne Terrance P. | EVP & CFO | Sale | 34.8K | $49.78 | $1.73M | 0 | View ↗ | |
| 2026-04-01 | Coyne Terrance P. | EVP & CFO | Sale | 34.8K | $48.33 | $1.68M | 32.9K | View ↗ | |
| 2026-03-23 | Coyne Terrance P. | EVP & CFO | Sale | 34.8K | $45.53 | $1.58M | 43.9K | View ↗ | |
| 2026-03-02 | Coyne Terrance P. | EVP & CFO | Sale | 34.8K | $46.78 | $1.63M | 45.8K | View ↗ | |
| 2026-02-23 | Coyne Terrance P. | EVP & CFO | Sale | 34.8K | $45.32 | $1.58M | 47.6K | View ↗ |
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total income and other revenues | $117.0M+2.5% | $114.2M-26.8% | $156.0M+109.0% | $74.6M+40.5% | $53.1M |
| Provision for changes in expected cash flows from financial royalty assets | -$295.8M-140.4% | $732.5M+30.6% | $560.7M-38.0% | $904.2M+99.7% | $452.8M |
| Provision for credit losses on unfunded commitments | $89.0M | $0 | $0 | — | — |
| Research and development funding expense | $452.0M+22500.0% | $2.0M-96.2% | $52.0M-70.6% | $177.1M-11.5% | $200.1M |
| General and administrative expenses (includes $290,890, $3,224, and $3,302 of share-based compensation expense for the years ended December 31, 2025, 2024 and 2023, respectively; see Note 4) | $573.5M+142.3% | $236.7M-5.2% | $249.7M | — | — |
| Total operating expense, net | $818.7M-15.7% | $971.1M+12.6% | $862.4M-55.3% | $1.93B | — |
| Operating income | $1.56B+20.7% | $1.29B-13.4% | $1.49B+385.9% | $307.1M-78.5% | $1.43B |
| Equity in earnings of equity method investees | -$29.1M+1.8% | -$29.6M-2.5% | -$28.9M | — | — |
| Interest expense | $307.7M+36.4% | $225.5M+20.5% | $187.2M-0.4% | $188.0M+13.1% | $166.1M |
| Losses on derivative financial instruments | $0-100.0% | $6.0M+162.0% | $2.3M | — | — |
| Losses/(gains) on equity securities | $21.9M+155.3% | -$39.5M+54.6% | -$87.1M | — | — |
| Gains on available for sale debt securities | -$45.9M+70.4% | -$154.9M+32.9% | -$230.8M | — | — |
| Interest income | -$33.6M+29.0% | -$47.3M+34.5% | -$72.3M+7.7% | -$78.3M-46.3% | -$53.5M |
| Other non-operating expenses, net | $14.3M+839.1% | $1.5M-93.0% | $21.7M+47.3% | $14.8M | — |
| Total other expense/(income), net | $235.3M+713.3% | -$38.4M+81.5% | -$207.9M | — | — |
| Consolidated net income before tax | $1.32B-0.5% | $1.33B-21.7% | $1.70B+639.0% | $230.1M-81.5% | $1.24B |
| Income tax expense | $0 | $0 | $0 | $0 | $0 |
| Consolidated net income | $1.32B-0.5% | $1.33B-21.7% | $1.70B+639.0% | $230.1M-81.5% | $1.24B |
| Net income attributable to non-controlling interests | $553.2M+17.3% | $471.8M-16.5% | $565.3M+201.9% | $187.2M-69.9% | $621.5M |
| Net income attributable to Royalty Pharma plc | $770.9M-10.2% | $859.0M-24.3% | $1.13B+2549.5% | $42.8M-93.1% | $619.7M |
| Basic (in dollars per share) | $2K-6.8% | $2K-24.4% | $3K+2440.0% | $100-93.3% | $1K |
| Diluted (in dollars per share) | $2K-6.8% | $2K-24.5% | $3K+2430.0% | $100-93.3% | $1K |
| Basic (in shares) | $429.8M-4.1% | $448.2M+0.1% | $447.6M+2.2% | $438.0M+5.6% | $414.8M |
| Diluted (in shares) | $564.5M-5.0% | $594.1M-1.5% | $602.9M+37.7% | $438.0M+5.6% | $414.8M |
| Income from financial royalty assets | |||||
| Total income and other revenues | $117.0M+2.5% | $114.2M-26.8% | $156.0M+109.0% | $74.6M+40.5% | $53.1M |
| Other royalty income and revenues | |||||
| Total income and other revenues | $117.0M+2.5% | $114.2M-26.8% | $156.0M+109.0% | $74.6M+40.5% | $53.1M |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Codexis (CDXS) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
Royalty Pharma (RPRX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
A Look At Royalty Pharma (RPRX) Valuation After Its Recent Share Price Momentum
Zymeworks Highlights Royalty-Fueled Pivot at Bloom Burton, Eyes Multibillion-Dollar Ziihera